explore -WSS

explore

author：entertainment 2025-09-03 03:19:42 - browse：128

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Alabama hospital puts IVF treatments on hold

leisure time

WSS

Abortion pill Supreme Court ruling could impact entire drug industry

Covid vaccine financial winners and losers, from Pfizer to Novavax

Roche subsidiary Foundation Medicine opens new headquarters

He's a Nobel laureate. Critics say he was misleading on Covid

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Antivenom research: Lessons from HIV applied in search for universal antidote

leisure time

explore

explore

Medical leaders decry Supreme Court decision on affirmative action

STAT readers on older presidents, polypills, Medicare, and more

Apple is now the first public company to be valued at $3 trillion

Why palliative psychiatry is worth discussing

Wildfire smoke exposes gaps in outdoor worker protections

Eliminate the waiting period for sterilization covered by Medicaid

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Antivenom research: Lessons from HIV applied in search for universal antidote

Medicare proposal to cover medical devices draws a mixed reaction

There's no autism epidemic. It's an autism diagnosis epidemic

Wikipedia

Antivenom research: Lessons from HIV applied in search for universal antidote

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Scientists boost immune system in aging mice by making it youthful

States should stop sabotaging methadone treatment reform

Patient advocates debate FDA's accelerated approval process

NIH study of ME/CFS points to clear biological hallmarks

leisure time

leisure time

hotspot

focus